Table 3

 Subgroup analyses of percentages of patients still positive for viral RNA at day 5 of treatment in samples taken from throat. Patients were grouped according to age, detected virus, and day of illness on enrolment

Standard doseDouble doseP value‡
No* (%)Copy number (range)†No with positive quantitative RT-PCR resultNo* (%)Copy number (range)†No with positive quantitative RT-PCR result
Age groups
All33/143 (23.1)3.85e+03 (1.00e+03-3.01e+05)1129/151 (19.2)1.83e+04 (1.00e+03-4.07e+05)140.40
<1829/116 (25)4.12e+03 (1.00e+03-3.01e+05)1023/119 (19.3)1.86e+04 (1.16e+03-1.45e+05)110.30
0-425/105 (23.8)4.12e+03 (1.00e+03-3.01e+05)1022/106 (20.8)1.95e+04 (2.06e+03-1.45e+05)100.60
5-174/11 (36.4)01/13 (7.7)1.16e+03 (1.16e+03−1.16e+03)10.08
≥184/27 (14.8)1.00e+03 (1.00e+03-1.00e+03)16/32(18.8)1.00e+03 (1.00e+03-4.07e+05)30.73
18-592/17 (11.8)1.00e+03 (1.00e+03-1.00e+03)15/27 (16.7)2.04e+05 (1.00e+03-4.07e+05)10.68
≥602/10 (20)01/2 (50)1.00e+03 (1.00e+03-1.00e+03)‘10.37
Virus type
1977 H1N14/23 (17.4)4.39e+03 (4.39e+03-4.39e+03)13/12 (25)1.79e+04 (1.21e+04-1.13e+05)30.59
H3N217/60 (28.3)3.85e+03 (2.08e+03-3.01e+05)515/71 (21.1)1.05e+04 (1.16e+03−1.45e+05)60.34
H1N1-pdm094/34 (11.8)1.00e+03 (1.00e+03-1.00e+03)13/37 (8.1)00.61
H5N10/0 (0)02/4 (50)2.04e+05 (1.00e+03-4.07e+05)2
B8/26 (30.8)4.58e+03 (1.00e+03-2.86e+04)46/27 (22.2)2.03e+04 (1.00e+03-3.44e+04)30.48
Time to treatment (days from onset of illness)
Within 25/17 (29.4)3.57e+03 (2.74e+03-4.39e+03)27/14 (50)2.39e+03 (1.00e+03-1.45e+05)50.24
Within 37/37 (18.9)3.57e+03 (2.74e+03−-4.39e+03)210/33 (30.3)1.01e+04 (1.00e+03-1.45e+05)80.27
Within 414/63 (22.2)2.41e+03 (1.00e+03-8.16e+03)615/61 (24.6)1.83e+04 (1.00e+03-1.45e+05)100.76
>419/80 (23.8)1.59e+04 (1.00e+03-3.01e+05)512/86 (14)1.21e+04 (1.00e+03-4.07e+05)3

RT-PCR=reverse transcriptase polymerase chain reaction.

*Patients still positive by qualitative RT-PCR in each arm per subgroup.

†Calculated from results of quantitative RT-PCR.

‡From χ2 for comparison of number of patients still positive by qualitative RT-PCR in each arm.